Molly Aldridge
Molly Aldridge has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Kristy Iglay
CERobs Consulting, LLC, Wrightsville Beach, USA
2 shared publications - Michael D. Kappelman
Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology, and Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
2 shared publications - Amy D. Shapiro
Indiana Hemophilia and Thrombosis Center, Indianapolis, IN
1 shared publication - Bharati Kochar
Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA
1 shared publication - Bruce E. Sands
Dr. Henry D. Janowitz Division of Gastroenterology Icahn School of Medicine at Mount Sinai New York New York USA
1 shared publication - Chitra Karki
Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA
1 shared publication
Latest Publications
- Open Access
- 11 November 2022
- Published by Wiley in Haemophilia
- Vol. 29 (2) , 423-434
Global epidemiology of factor XI deficiency: A targeted review of the literature and foundation reports
Introduction: Hereditary factor XI (FXI) deficiency is a rare coagulation disorder that may result in excessive bleeding requiring intervention to restore haemostasis.Aim: The aim of this review was to report the current knowledge of the worldwide incidence and prevalence of FXI deficiency.Methods: A targeted PubMed search using terms related to FXI deficiency was conducted to identify studies published from April 2002 through April 2022. A manual search supplemented the electronic search. Studies were eligible for data abstraction if they reported population‐based incidence proportions/rates or prevalence proportions for FXI deficiency.Results: The electronic and manual searches returned 253 publications. After applying exclusion criteria, seven publications were included in the analysis, including a global report from the World Federation of Haemophilia (WFH). Six publications provided information on the prevalence of FXI deficiency that included 74 countries and regions. The estimated prevalence of FXI in the WFH report ranged from 0/100,000 in several countries to 55.85/100,000 individuals in the United Kingdom. Prevalence estimates in the PubMed findings ranged from .1 to 246.2/1,000,000 inhabitants with varying methods of case identification and time periods of analysis. One study estimated the incidence of FXI deficiency in Yecla, Spain at 2% of blood donors and .09% of hospital inpatients/outpatients with activated partial thromboplastin time (aPTT) tests.Conclusion: FXI deficiency is rare across the world, but additional steps could be taken to improve incidence and prevalence estimation, for example, development of a consistent FXI deficiency definition and incorporating genetic testing into a clinical routine to better identify and characterise cases.
- 11 November 2022
- Published by Wiley in Haemophilia
- Vol. 29 (2) , 423-434
Open AccessGlobal epidemiology of factor XI deficiency: A targeted review of the literature and foundation reports
Introduction: Hereditary factor XI (FXI) deficiency is a rare coagulation disorder that may result in excessive bleeding requiring intervention to restore haemostasis.Aim: The aim of this review was to report the current knowledge of the worldwide incidence and prevalence of FXI deficiency.Methods: A targeted PubMed search using terms related to FXI deficiency was conducted to identify studies published from April 2002 through April 2022. A manual search supplemented the electronic search. Studies were eligible for data abstraction if they reported population‐based incidence proportions/rates or prevalence proportions for FXI deficiency.Results: The electronic and manual searches returned 253 publications. After applying exclusion criteria, seven publications were included in the analysis, including a global report from the World Federation of Haemophilia (WFH). Six publications provided information on the prevalence of FXI deficiency that included 74 countries and regions. The estimated prevalence of FXI in the WFH report ranged from 0/100,000 in several countries to 55.85/100,000 individuals in the United Kingdom. Prevalence estimates in the PubMed findings ranged from .1 to 246.2/1,000,000 inhabitants with varying methods of case identification and time periods of analysis. One study estimated the incidence of FXI deficiency in Yecla, Spain at 2% of blood donors and .09% of hospital inpatients/outpatients with activated partial thromboplastin time (aPTT) tests.Conclusion: FXI deficiency is rare across the world, but additional steps could be taken to improve incidence and prevalence estimation, for example, development of a consistent FXI deficiency definition and incorporating genetic testing into a clinical routine to better identify and characterise cases.
- Open Access
- 11 November 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (45) , e30963
A systematic review of epidemiology and outcomes of Crohn’s disease-related enterocutaneous fistulas
Background: Enterocutaneous fistulas (ECF) are rare sequelae of Crohn’s disease (CD) that occur either postoperatively or spontaneously. ECFs are associated with high morbidity and mortality. This systematic literature review assesses the disease burden of CD-related ECF and identifies knowledge gaps around incidence/prevalence, treatment patterns, clinical outcomes, healthcare resource utilization (HCRU), and patient-reported outcomes (PROs). Methods: English language articles published in PubMed and Embase in the past 10 years that provided data and insight into the disease burden of CD-related ECF (PROSPERO Registration number: CRD42020177732) were identified. Prespecified search and eligibility criteria guided the identification of studies by two reviewers who also assessed risk of bias. Results: In total, 582 records were identified; 316 full-text articles were assessed. Of those, eight studies met a priori eligibility criteria and underwent synthesis for this review. Limited epidemiologic data estimated a prevalence of 3265 persons with ECF in the USA in 2017. Clinical response to interventions varied, with closure of ECF achieved in 10% to 62.5% of patients and recurrence reported in 0% to 50% of patients. Very little information on HCRU is available, and no studies of PROs in this specific population were identified. Conclusion: The frequency, natural history, and outcomes of ECF are poorly described in the literature. The limited number of studies included in this review suggest a high treatment burden and risk of substantial complications. More robust, population-based research is needed to better understand the epidemiology, natural history, and overall disease burden of this rare and debilitating complication of CD.
- 11 November 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (45) , e30963
Open AccessA systematic review of epidemiology and outcomes of Crohn’s disease-related enterocutaneous fistulas
Background: Enterocutaneous fistulas (ECF) are rare sequelae of Crohn’s disease (CD) that occur either postoperatively or spontaneously. ECFs are associated with high morbidity and mortality. This systematic literature review assesses the disease burden of CD-related ECF and identifies knowledge gaps around incidence/prevalence, treatment patterns, clinical outcomes, healthcare resource utilization (HCRU), and patient-reported outcomes (PROs). Methods: English language articles published in PubMed and Embase in the past 10 years that provided data and insight into the disease burden of CD-related ECF (PROSPERO Registration number: CRD42020177732) were identified. Prespecified search and eligibility criteria guided the identification of studies by two reviewers who also assessed risk of bias. Results: In total, 582 records were identified; 316 full-text articles were assessed. Of those, eight studies met a priori eligibility criteria and underwent synthesis for this review. Limited epidemiologic data estimated a prevalence of 3265 persons with ECF in the USA in 2017. Clinical response to interventions varied, with closure of ECF achieved in 10% to 62.5% of patients and recurrence reported in 0% to 50% of patients. Very little information on HCRU is available, and no studies of PROs in this specific population were identified. Conclusion: The frequency, natural history, and outcomes of ECF are poorly described in the literature. The limited number of studies included in this review suggest a high treatment burden and risk of substantial complications. More robust, population-based research is needed to better understand the epidemiology, natural history, and overall disease burden of this rare and debilitating complication of CD.
- Open Access
- 3 June 2016
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 18 (6) , e124
Achieving Synergy: Linking an Internet-Based Inflammatory Bowel Disease Cohort to a Community-Based Inception Cohort and Multicentered Cohort in Inflammatory Bowel Disease
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet
- 3 June 2016
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 18 (6) , e124
Open AccessAchieving Synergy: Linking an Internet-Based Inflammatory Bowel Disease Cohort to a Community-Based Inception Cohort and Multicentered Cohort in Inflammatory Bowel Disease
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet